Algernon Pharmaceuticals Inc.

DB:AGW0 Stock Report

Market Cap: €1.5m

Algernon Pharmaceuticals Management

Management criteria checks 4/4

Algernon Pharmaceuticals' CEO is Chris Moreau, appointed in Mar 2018, has a tenure of 6.5 years. total yearly compensation is CA$544.30K, comprised of 40.4% salary and 59.6% bonuses, including company stock and options. directly owns 5.62% of the company’s shares, worth €86.43K. The average tenure of the management team and the board of directors is 3.5 years and 3.9 years respectively.

Key information

Chris Moreau

Chief executive officer

CA$544.3k

Total compensation

CEO salary percentage40.4%
CEO tenure6.5yrs
CEO ownership5.6%
Management average tenure3.5yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Moreau's remuneration changed compared to Algernon Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
May 31 2024n/an/a

-CA$3m

Feb 29 2024n/an/a

-CA$5m

Nov 30 2023n/an/a

-CA$5m

Aug 31 2023CA$544kCA$220k

-CA$7m

May 31 2023n/an/a

-CA$6m

Feb 28 2023n/an/a

-CA$6m

Nov 30 2022n/an/a

-CA$7m

Aug 31 2022CA$576kCA$220k

-CA$6m

May 31 2022n/an/a

-CA$4m

Feb 28 2022n/an/a

-CA$5m

Nov 30 2021n/an/a

-CA$6m

Aug 31 2021CA$256kCA$220k

-CA$8m

May 31 2021n/an/a

-CA$10m

Feb 28 2021n/an/a

-CA$13m

Nov 30 2020n/an/a

-CA$12m

Aug 31 2020CA$257kCA$157k

-CA$9m

May 31 2020n/an/a

-CA$6m

Feb 29 2020n/an/a

-CA$2m

Nov 30 2019n/an/a

-CA$2m

Aug 31 2019CA$108kCA$108k

-CA$2m

May 31 2019n/an/a

-CA$2m

Feb 28 2019n/an/a

-CA$2m

Nov 30 2018n/an/a

-CA$1m

Aug 31 2018CA$108kCA$54k

-CA$938k

Compensation vs Market: Chris's total compensation ($USD404.03K) is about average for companies of similar size in the German market ($USD508.57K).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Moreau (59 yo)

6.5yrs

Tenure

CA$544,302

Compensation

Mr. Christopher J. Moreau, also known as Chris, has been Chief Executive Officer and Director at Algernon Neuroscience Inc., since December 9, 2022. He has been Chief Executive Officer at Algernon Pharmace...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Moreau
CEO & Director6.5yrsCA$544.30k5.62%
CA$ 86.4k
James Kinley
Chief Financial Officer2.8yrsCA$290.10k3.85%
CA$ 59.2k
Christopher Bryan
Vice President of Research & Operations3.5yrsCA$300.10kno data

3.5yrs

Average Tenure

46yo

Average Age

Experienced Management: AGW0's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Moreau
CEO & Director4.3yrsCA$544.30k5.62%
CA$ 86.4k
Harold J. Bloomfield
Independent Chairman of the Board3yrsCA$187.17k1.41%
CA$ 21.6k
Howard Gutman
Director2.6yrsCA$93.43k0.64%
CA$ 9.8k
Peter Dicpinigaitis
Medical Consultant of Chronic Cough Research Prgm. & Member of Medical and Scientific Advisory Board1.7yrsno datano data
Rajpaul Attariwala
Independent Director8.9yrsCA$81.94k0.42%
CA$ 6.5k
David Nutt
Member of Medical & Scientific Advisory Boardno datano datano data
Mark Williams
Director3yrsCA$86.94k0.16%
CA$ 2.5k
Martin Kolb
Member of Medical & Scientific Advisory Board4.8yrsno datano data
Jacky Smith
Member of Medical & Scientific Advisory Board4.6yrsno datano data
Mark Swaim
Member of Medical & Scientific Advisory Board3.9yrsno datano data
Rick Strassman
Member of Medical & Scientific Advisory Boardno datano datano data
Ede Frecska
Member of Medical & Scientific Advisory Boardno datano datano data

3.9yrs

Average Tenure

59yo

Average Age

Experienced Board: AGW0's board of directors are considered experienced (3.9 years average tenure).